{
    "clinical_study": {
        "@rank": "127799", 
        "arm_group": {
            "arm_group_label": "Erlotinib or Gefitinib", 
            "arm_group_type": "Experimental", 
            "description": "Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg  every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period  takes about 12 months"
        }, 
        "brief_summary": {
            "textblock": "the purpose of this study is to evaluate the efficacy and safety of high-dose\uff0cpulsatile\n      Erlotinib/Gefitinib in advanced non small cell lung cancer (NSCLC) patients after failure of\n      standard dose EGFR-TKIs\uff08Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors\uff09"
        }, 
        "brief_title": "High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Self Efficacy", 
            "Drug Toxicity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Drug Toxicity"
            ]
        }, 
        "detailed_description": {
            "textblock": "To evaluate the efficacy and safety by treating the advanced non small cell lung cancer\n      (NSCLC) patients who have failure of  standard dose EGFR-TKIs(Erlotinib or Gefitinib ) with\n      high-dose, pulsatile Erlotinib(450mg every 3 days) or Gefitinib (1000mg every 4 days)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. NSCLC patients were confirmed by histology or cytology 2.  Patients were ever\n             treated with standard dose EGFR-TKIs(Erlotinib or Gefitinib )on which he/she achieved\n             complete remission/partial remission,or maintained stable disease for 4\n             months.Disease progression at present (accord to RECISTv1.1 criteria\uff09 3.At least one\n             target lesion that has not previously been radiated and is measurable according to\n             RECIST v1.1; 4.Have an ECOG PS of 0-2 5.At least 8 weeks of expected survival time\n             6.Have no serious cardiovascular,hepatobiliary or renal disorders 7.Provision of a\n             voluntarily given, personally signed and dated, written informed consent document\n             8.Must be in accordance with the following laboratory biochemical data:\n             Hgb\u226580g/L\uff0cWBC\u22653.0\u00d710^9/L\uff0cANC\u22651.0\u00d710^9/L\uff0c PLT\u226580\u00d710^9/L Renal function\uff1aSCr\u2264ULN Liver\n             function\uff1a if no hepatic metastases:AST/ALT\u22642.5ULN if hepatic metastases:AST/ALT\u22645ULN\n\n        Exclusion Criteria:\n\n          -  If the subject meet any of the following exclusion criteria ,he/she is no eligible to\n             participate in this study\n\n               1. Have chronic toxicity reaction(above grade 2) and not recovered( hair loss not\n                  include)\n\n               2. Have Appeared skin rashes or diarrhea(above grade 3),or have any reason lead to\n                  decrement during standard dose EGFR-TKIs treatment\n\n               3. Female subjects who are in pregnancy or lactation\uff0cor of childbearing age  but\n                  don't take any contraceptive measures\n\n               4. Current enrollment in another therapeutic clinical study\n\n               5. Have any symptoms of brain metastases or leptomeningeal metastases\n\n               6. Subjects will not be eligible if they have history of prior malignancy in past 5\n                  years\n\n               7. Any psychiatric or cognitive disorder that would limit the understanding or\n                  rendering of informed consent and/or compromise compliance with the requirements\n                  of this study or known drug abuse/alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965275", 
            "org_study_id": "HDP-ADNSCLC"
        }, 
        "intervention": {
            "arm_group_label": "Erlotinib or Gefitinib", 
            "description": "Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months", 
            "intervention_name": "Erlotinib or Gefitinib", 
            "intervention_type": "Drug", 
            "other_name": "high-dose, pulsatile Erlotinib or Gefitinib"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gefitinib", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Advanced non-small cell lung cancer", 
            "High-dose", 
            "Pulsatile", 
            "EGFR-TKIs"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "contact": {
                "email": "yanzhe918@163.com", 
                "last_name": "Yanzhe Zhu, MD", 
                "phone": "8655162922987"
            }, 
            "facility": {
                "address": {
                    "city": "Hefei", 
                    "country": "China", 
                    "state": "Anhui", 
                    "zip": "230032"
                }, 
                "name": "Dept. of Oncology,The First Affiliated Hospital of Anhui Medical Univesrsity"
            }, 
            "investigator": {
                "last_name": "Yueyin Pan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open,Multi Center Trial to Evaluate the Efficacy and Safety of High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced Non-Small Cell Lung Cancer Patients After Failure of Standard Dose EGFR-TKIs", 
        "overall_contact": {
            "email": "yanzhe918@163.com", 
            "last_name": "Yanzhe Zhu, MD", 
            "phone": "8655162922987"
        }, 
        "overall_official": {
            "affiliation": "Anhui Medical University", 
            "last_name": "Yueyin Pan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the efficacy and safety  by treating the advanced NSCLC patients who have failure of  standard dose EGFR-TKIs with high-dose, pulsatile Erlotinib(600mg every 4 days) or Gefitinib (1000mg every 4 days)\nRadiologically measurable disease by RECIST v1.1 criteria:\nAt least one target lesion that has not previously  been radiated and is measurable according to RECIST v1.1;\nAcceptable radiologic procedures for disease assessment include contrast enhanced conventional or spiral computed tomography (CT), or contrast enhanced magnetic resonance imaging (MRI);  Non-contrast CT scan is acceptable only for subjects who are both allergic to intravenous contrast and unable to cooperate with MRI, or MRI is not available.  The following are not allowed as sole documentation of target lesions: CT component of a positron emission tomography (PET)/CT,ultrasound alone, nuclear scans (including bone or PET scans), chest X-ray  or bone radiographs, and tumor markers", 
            "measure": "efficacy and safety", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965275"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Anhui Medical University", 
            "investigator_full_name": "Pan Yueyin", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Anhui Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anhui Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}